NovoCure Ltd
About NovoCure Ltd
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $655.4M
- Net income
- -$136.2M
- Total assets
- $804.3M
- Market cap
- $2.0B
- Gross margin
- 74.5%
- Operating margin
- -23.5%
- Net margin
- -20.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $655.4M
- Cost of revenue
- $166.9M
- Gross profit
- $488.5M
- Operating expenses
- $642.3M
- Operating income
- -$153.8M
- Income tax
- -$23.0K
- Net income
- -$136.2M
- EPS (basic)
- $-1.22
- EPS (diluted)
- $-1.22
Balance sheet
- Total assets
- $804.3M
- Current assets
- $646.7M
- Total liabilities
- $463.9M
- Current liabilities
- $223.2M
- Shareholders’ equity
- $340.5M
Cash flow
- Operating cash flow
- -$49.0M
- Investing cash flow
- $437.3M
- Financing cash flow
- -$451.3M
- Net cash flow
- -$62.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.0B
- EPS (diluted)
- $-1.22
- Shares outstanding
- 118.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 2, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $136.2M in FY2025.
- Revenue grew 33% from FY2020 to FY2025.
- Gross margin of 74.5%, net margin -20.8%.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NovoCure Ltd.
Write a review
News about NovoCure Ltd
News & sentiment via Polygon.io
